|1.||Chwalisz, Kristof: 15 articles (09/2013 - 11/2003)|
|2.||Maruo, Takeshi: 8 articles (09/2011 - 04/2006)|
|3.||Ohara, Noriyuki: 8 articles (09/2011 - 04/2006)|
|4.||Yoshida, Shigeki: 6 articles (09/2011 - 04/2006)|
|5.||Xu, Qin: 6 articles (09/2011 - 04/2006)|
|6.||Sasaki, Hiroko: 5 articles (09/2011 - 04/2006)|
|7.||Morikawa, Akira: 5 articles (05/2010 - 04/2006)|
|8.||Wang, Jiayin: 5 articles (05/2010 - 04/2006)|
|9.||Elger, Walter: 5 articles (06/2007 - 11/2003)|
|10.||Nakabayashi, Koji: 4 articles (09/2011 - 10/2007)|
|1.||Leiomyoma (Uterine Fibroids)
12/01/2007 - "The authors review studies they conducted to evaluate the comparative effects of asoprisnil on proliferation, apoptosis, and growth factor expression in cultured leiomyoma and normal myometrial cells. "
10/01/2007 - "The present study was conducted to examine whether asoprisnil elicits endoplasmic reticulum (ER) stress-induced apoptosis in cultured human uterine leiomyoma cells. "
12/01/2008 - "Furthermore, we assessed effects of asoprisnil on leiomyoma symptoms. "
10/01/2007 - "RNA interference of GADD153 suppressed protein contents of asoprisnil-induced cleaved PARP, Bax, Bak, GADD34, and tribbles-related protein 3 (TRB3) and TUNEL-positive rate but attenuated asoprisnil-induced reduction in Bcl-2 protein content in cultured leiomyoma cells. "
02/01/2007 - "The concomitant treatment with 100 ng/ml P4 significantly (P < 0.05) reversed asoprisnil-induced increase in DR4 and cleaved poly(adenosine 5'-diphosphate-ribose) polymerase contents in cultured leiomyoma cells. "
01/01/2006 - "The SPRM asoprisnil is being studied in women with symptomatic uterine leiomyomata and endometriosis. "
11/01/2003 - "With favorable safety and tolerability profiles thus far, asoprisnil appears promising as a novel treatment of gynecological disorders, such as uterine fibroids and endometriosis."
05/01/2007 - "One such SPRM, asoprisnil, was recently in clinical trials for treatment of uterine fibroids and endometriosis. "
05/01/2005 - "Asoprisnil may, therefore, provide a novel, tissue-selective approach to control endometriosis-related pain. "
05/01/2005 - "Asoprisnil (J867) is the first SPRM to reach an advanced stage of clinical development for the treatment of symptomatic uterine fibroids and endometriosis. "
06/01/2013 - "Premenopausal women aged ≥18 years with heavy menstrual bleeding (HMB) associated with uterine leiomyomata were randomized to asoprisnil (10 or 25 mg) or placebo. "
12/01/2008 - "Bleeding was suppressed by asoprisnil 25mg in 91% of patients. "
12/01/2008 - "Analysis of menstrual pictogram scores showed a statistically significant larger decrease in frequency and intensity of bleeding for both asoprisnil groups compared with placebo. "
09/01/2013 - "We have previously reported suppression of endometrial bleeding and alteration of spiral artery morphology in women exposed to asoprisnil, a progesterone receptor modulator. "
09/01/2013 - "Uterine NK cells regulate endometrial bleeding in women and are suppressed by the progesterone receptor modulator asoprisnil."
|2.||Mifepristone (RU 486)
|3.||Progesterone Receptors (Progesterone Receptor)
|4.||epigallocatechin gallate (epigallocatechin-3-gallate)
|6.||Intercellular Signaling Peptides and Proteins (Growth Factors)
|7.||Proteins (Proteins, Gene)
|8.||TNF-Related Apoptosis-Inducing Ligand